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Abstracts / Osteoarthritis and Cartilage 22 (2014) S57–S489S164more reactive cells, the mitochondrial signals showed a perinuclear
distribution.
Kinetic evaluation of the cells treated with LiCl across 8, 16, 24 , 48 and
72 hours showed that GSK3b inactivation impacts on cellular pro-
liferation, with evident reduction particularly at 24 hours post stim-
ulation. Noteworthy, cell cycle analysis consistently showed increased
percentage of cells in the S phase at this time point. The histochemical
SA-b Gal staining conﬁrmed that GSK3b inhibition increases cell sen-
escence, despite an already appreciable basal level, possibly due to the
osteoarthritic nature of the samples. Noteworthy, the cells showing
stronger level of SA-b galactosidase were larger than the other cells and
“hypertrophic”. The same information was achieved by PAS staining
that revealed a stronger content of glycogen in hypertrophic cells which
increased in samples treated with LiCl compared with the unstimulated
chondrocytes. Flow cytometric analysis conﬁrmed that larger cells
accumulated upon LiCl treatment, particularly in the S Phase, already at
8 hours stimulation, as evidenced by their increased forward scatter.
Collectively, following GSK3b inactivation, western blot and ﬂow cyto-
metric analysis supported the occurrence of a DNA damage response
leading to cellular senescence with increase in gH2AX, GADD45b and
p21.
Conclusions: We have found that GSK3b activity in OA chondrocytes is
essential for maintenance of their proliferative potential and that its
inactivation also appreciably affects the mitochondrial function, being
responsible for the production of reactive oxygen species. This in turn
triggers the induction of a DNA damage response via the axis
gH2AX>GADD45b> p21which leads to survival of chondrocytes but to
their functional impairment via induction of hypertrophy and
senescence.
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SPRIFERMIN (RHFGF18) HAS AN ANABOLIC EFFECT ON HUMAN
OSTEOARTHRITIC CHONDROCYTES INVOLVING FGFR3 AND ERK1/2
BUT NOT P38a AND JNKS
A. Gigout, S. Lindemann, H. Guehring. Merck Serono, Merck KGaA,
Darmstadt, Germany
Purpose: Restoring the articular surface of degraded or largely injured
cartilage necessitates cartilage re-cellularization and the stimulation of
cartilagematrix molecule production. Sprifermin (currently in a phase II
clinical trial for knee osteoarthritis) is a growth factor that is involved in
chondrogenesis and exerts an anabolic effect on cartilage. Using a 3D
cell culture system, we previously demonstrated the ability of Spri-
fermin to stimulate cartilage matrix molecule expression and to pro-
mote the chondrocyte phenotype in bovine and porcine articular
chondrocytes. In the present work, we aimed to conﬁrm this effect in
osteoarthritic chondrocytes of human origin (hOA). In parallel, the
pathways involved in Sprifermin signaling were investigated in porcine
chondrocytes.
Methods: Primary osteoarthritic chondrocytes were isolated from the
cartilage of patients who underwent total knee replacement. Cells were
cultivated for a few days in monolayer ﬁrst and then for one week in
scaffold-free 3D culture before starting the treatment. The latter con-
sisted in the incubation with Sprifermin [100 ng/mL] permanently or
one day/week for a total period of four weeks. Results were compared to
a control culture without Sprifermin. Biochemical assays, quantitative
PCR (qPCR) and histology were used to characterize the 3D constructs.
FGFR expression by qPCR and activation of various kinases (with the
human phospho-MAPK array kit from R&D Systems) upon Sprifermin
stimulation were assessed on freshly isolated hOA chondrocytes. The
effects of a panel of inhibitors (MAPK inhibitors and one pan-FGFR
inhibitor) were tested in porcine cells. For this, freshly isolated chon-
drocytes from a pig hip were cultivated for 7 days in monolayer with
100 ng/mL of Sprifermin in presence of three concentrations of the
inhibitors (0.1, 0.3 and 1 mM or 1, 3 and 10 mM depending on their
potency). Sprifermin has been previously shown to strongly decrease
the collagen I expression (monitored by qPCR) and to promote a round
cell morphology (evaluated by actin staining) of porcine chondrocytes
in monolayer. These parameters were used to evaluate the impact of the
various inhibitors.
Results: A 3D scaffold-free culture was used to test the effect of Spri-
fermin on hOA chondrocytes. In this setting Sprifermin [1day/week] hasbeen found to have a positive effect on the cell content and to greatly
increase the size and matrix content of the 3D constructs.
In accordance with the literature, FGFR1 and 3 exhibited the highest
expression among FGFRs in hOA chondrocytes. In addition, Sprifermin
effects were suppressed by FGFR inhibition. In porcine chondrocytes
cultivated in monolayer, Sprifermin strongly inhibited collagen I
expression and promoted a round cell shape. Both effects were com-
pletely inhibited in presence of the pan-FGFR inhibitor PD173074 in a
dose-dependent manner. Because FGF18 does not bind FGFR1, in
chondrocytes Sprifermin signaling involves mainly FGFR3.
Upon incubation with Sprifermin [100 ng/mL], ERK1/2 was activated as
well as p38g, but not p38a or the JNKs. The ERK inhibitor PD325901
completely inhibited the effect of Sprifermin on cell morphology at 100
nM. The JNK inhibitor (SR3306) and p38 inhibitors (BIRB-796 and
SB203580) did not have any effect. The effect of these inhibitors on
collagen I expression is still under investigation. Taken together these
results indicate that ERK1/2 is involved in Sprifermin signaling whereas
p38a and JNKs are not.
Conclusions: As observed in previous studies with bovine and porcine
chondrocytes, Sprifermin was found to exert anabolic effects in hOA
chondrocytes. These effects seem to be mediated by FGFR3 and ERK1/2
activation. Others demonstrated that ERK1/2 is also involved in FGF2-
FGFR1 signaling but in this case led to a catabolic response. This dif-
ference can be possibly explained by the fact that JNK and p38 are also
activated by FGF2-FGFR1 signaling but not by FGF18-FGFR3.
272
HIF-1a REGULATES CONFIGURATION AND MAINTENANCE OF
ARTICULAR CARTILAGE THROUGH INDUCTION OF ANABOLIC
FACTORS AND SUPPRESSION OF CATABOLIC FACTORS
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Purpose: Hypoxia-inducible factor-1a (HIF-1a) plays a crucial role in
hypoxic conditions for cell survival in various tissues. In chondrocytes,
previous studies showed that HIF-1a was necessary for chondrocyte
survival in endochondral ossiﬁcation and for interzone formation in
joint development; however, the underlying molecular mechanisms
remain unclear. Moreover, physiological and pathological functions of
HIF-1a in articular cartilage are yet to be revealed. Here we have
investigated HIF-1a functions and the underlying mechanisms of the
conﬁguration and maintenance of articular cartilage by HIF-1a.
Methods: We generated tissue-speciﬁc knockout mice of HIF-1a by
mating Sox9-Cre knock-in mice (Sox9-Cre) or tamoxifen-inducible
Col2a1-Cre transgenic mice (Col2a1-CreERT2), with mice homozygous
for a ﬂoxed Hif1a allele (Hif1aﬂ/ﬂ). For analyses of cartilage conﬁg-
uration, we examined Sox9-Cre;Hif1aﬂ/ﬂmice at E15.5, E18.5 and P1. To
analyze articular cartilage maintenance and osteoarthritis (OA) pro-
gression after maturation, we injected tamoxifen into 7-week-old
Col2a1-CreERT2;Hif1aﬂ/ﬂ mice, and created a surgical OA model by
inducing instability in the knee joints one week later. OA severity was
quantiﬁed by the OARSI histopathology grade 8 weeks after surgery. For
histological analyses of these knockout mice, we performed Safranin O
staining, TUNEL staining, and immunoﬂuorescence. Quantitative gene
expression in limb cartilages of Sox9-Cre;Hif1aﬂ/ﬂ and the control
Hif1aﬂ/ﬂ neonates was determined based on real-time RT-PCR analyses
using samples obtained directly from their limb cartilages. To assess the
catabolic ability of HIF-1a, we measured the concentration of aggrecan
released from the 3-week-old mouse femoral heads cultured with or
without CoCl2, a potent enhancer of HIF-1a protein stability, utilizing
dimethylmethylene blue dye-binding assay. Mouse primary articular
chondrocytes were used for further in vitro functional analyses.
Results: Sox9-Cre;Hif1aﬂ/ﬂ embryos and neonates showed dwarﬁsm
with severe limb shortening throughout the embryonic stages and died
in the perinatal period. This phenotype was consistent with previous
reports using Prx1-Cre and Col2a1-Cre mice. Notably, the knee joints of
Sox9-Cre;Hif1aﬂ/ﬂ embryos showed a widespread epiphysis with a
massive cavity continuing from the joint surface forming a trumpet
shape, in which the columnar architecture was completely abolished
and the cell numbers were vastly reduced(Fig.1). Safranin O staining
